Loading...

PolarityTE, Inc.

PTE•NASDAQ
Healthcare
Biotechnology
$0.24
$-0.00(-0.82%)

PolarityTE, Inc. (PTE) Stock Overview

Explore PolarityTE, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 66.1/100

Key Financials

Market Cap1.8M
P/E Ratio0.16
EPS (TTM)$-0.58
ROE0.57%

AI Price Forecasts

1 WeekN/A
1 MonthN/A
3 MonthsN/A
1 Year Target$0.10

PTE Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of PolarityTE, Inc. (PTE) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $0.10.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 0.16 and a market capitalization of 1.8M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Stats data is not available for PTEStats details for PTE are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for PTEAnalyst Recommendations details for PTE are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

PolarityTE, Inc., a clinical stage biotechnology company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine Products and Contract Services. It offers SkinTE, a tissue product used to repair, reconstruction, replacement, and supplementation of skin in patients for the treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts, as well as contract research services. The company also develops SkinTE Cryo allows multiple deployments from one original harvest through a cryopreservation process; SkinTE point-of-care device to permit the processing and deployment of SkinTE immediately following the initial harvest at the point-of-car; PTE 11000, an allogenic, biologically active dressing for use in wound care and aesthetics to accelerate healing of skin; and other tissue regeneration products. PolarityTE, Inc. is headquartered in Salt Lake City, Utah.

CEO

Richard Hague

Employees

42

Headquarters

1960 South 4250 West, Salt Lake City, UT

Founded

1999

Frequently Asked Questions

;